MR Antagonist and LSD1

Lysine specific demethylase-1 (LSD1) is an epigenetic regulator of gene transcription involved in the pathophysiology of elevated blood pressure and likely renal damage in Blacks. This project investigates whether a genetically driven anti-hypertensive approach proves superior in controlling blood pressure and mitigating renal injury in Blacks who carry the risk allele for LSD1 (rs587168). The findings of these investigations may lead to a new approach in treating a subset (\~30%) of the essential hypertension population (Black LSD1 risk allele hypertensives).

NCT Number	NCT04840342
Lead Sponsor	Brigham and Women's Hospital
Conditions	Hypertension, Mineralocorticoid Excess
Enrollment	300 participants
Start Date	2022-02-03
Primary Completion	2025-09-15 (estimated)
Study Completion	2026-06 (estimated)
Updated on ClinicalTrials.gov	2026-04-29